AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

AbbVie (NYSE: ABBV) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will take part in a fireside chat at 10:10 a.m. Central Time. A live audio webcast and an archived edition will be available via AbbVie's investor site.

News Market Reaction – ABBV

-0.45%

-0.45% Session close to close

In the Feb 24 session, ABBV declined 0.45%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights AbbVie’s participation in a high-profile healthcare conference, offerin...

Analysis

This announcement highlights AbbVie’s participation in a high-profile healthcare conference, offering management another platform to communicate strategy and portfolio priorities. In context of recent earnings, dividend actions, and regulatory milestones, the event continues a steady flow of investor outreach. Key considerations include how messaging aligns with previously issued 2026 EPS guidance, the role of growth drivers like Skyrizi and Rinvoq, and ongoing exposure to pricing, patent, and competitive risks outlined in recent regulatory filings.

Key Figures

Conference fireside chat time: 10:10 a.m. Central Time Quarterly dividend: $1.73 per share Dividend growth: 330% +5 more

8 metrics

Conference fireside chat time 10:10 a.m. Central Time TD Cowen 46th Annual Health Care Conference on March 3, 2026

Quarterly dividend $1.73 per share Declared payable May 15, 2026 to holders of record April 15, 2026

Dividend growth 330% Dividend increase since 2013

2025 net revenues $61.160 billion Full-year 2025 net revenues (+8.6% reported)

2025 GAAP diluted EPS $2.36 Full-year 2025 GAAP diluted EPS

2025 adjusted EPS $10.00 Full-year 2025 adjusted diluted EPS

Q4 2025 revenues $16.618 billion Fourth-quarter 2025 revenues (+10.0% reported)

2026 EPS guidance $14.37–$14.57 2026 adjusted diluted EPS guidance, excluding acquired IPR&D and milestones

Historical Context

5 past events · Latest: Feb 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 20	FDA approval	Positive	-0.2%	FDA approved VENCLEXTA plus acalabrutinib for first-line CLL patients.
Feb 19	Dividend declaration	Positive	-1.9%	Board declared a quarterly cash dividend of $1.73 per share.
Feb 04	Earnings results	Positive	-3.8%	Reported 2025 results with $61.160B revenue and issued 2026 EPS guidance.
Feb 03	Brand program launch	Neutral	+0.0%	Allergan Aesthetics launched Faces of Natrelle testimonial program.
Feb 03	Regulatory submissions	Positive	+0.0%	Submitted FDA and EMA applications for Rinvoq in vitiligo based on Phase 3 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive catalysts (earnings, dividend increase, FDA approval) often saw negative next-day moves, suggesting a pattern of selling into good news.

Recent Company History

Over the last few weeks, AbbVie reported strong 2025 results, with full-year net revenues of $61.160 billion and key growth from Skyrizi and Rinvoq, issued 2026 EPS guidance, declared a higher quarterly dividend of $1.73 per share, and secured FDA approval for a new CLL combination regimen. Despite these constructive updates, next-day price reactions to earnings, dividend, and FDA approval were modestly negative, indicating investors had already priced in much of the good news. Today’s conference appearance fits into this active communication cadence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Media: Gabby Tarbert (224) 244-0111 gabrielle.tarbert@abbvie.com

Investors: Liz Shea (847) 935-2211 liz.shea@abbvie.com

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-td-cowen-46th-annual-health-care-conference-302692181.html

SOURCE AbbVie

FAQ

When will AbbVie (ABBV) present at the TD Cowen 46th Annual Health Care Conference?

AbbVie will present on Tuesday, March 3, 2026, with management in a fireside chat at 10:10 a.m. Central Time. According to the company, the session is part of the conference schedule and will be delivered live and archived for later access.

How can investors access AbbVie (ABBV) webcast from the March 3, 2026 presentation?

Investors can access a live audio webcast through AbbVie's investor relations website at investors.abbvie.com. According to the company, an archived edition of the session will be posted later that day for on‑demand listening.

What format is AbbVie's (ABBV) presentation at the March 3, 2026 TD Cowen conference?

AbbVie's presentation will be a management fireside chat starting at 10:10 a.m. Central Time on March 3, 2026. According to the company, the event is presented as an audio webcast with an archived edition available later that day.

Will AbbVie's (ABBV) March 3, 2026 TD Cowen session be available after the live event?

Yes. An archived edition of the March 3, 2026 session will be available later that day on AbbVie's investor relations website. According to the company, the archived audio will allow investors to listen on demand after the live webcast.

What time should investors tune in for AbbVie's (ABBV) fireside chat on March 3, 2026?

Investors should tune in at 10:10 a.m. Central Time on March 3, 2026 for the fireside chat. According to the company, the session will be streamed as a live audio webcast and later archived on the investor relations site.